Valneva: EMA starts review of Covid-19 vaccine

(CercleFinance.com) - French biotech company Valneva has confirmed that the European Medicines Agency (EMA) has begun a phased review of the registration dossier for VLA2001, its whole-virus, inactivated, adjuvanted Covid-19 vaccine candidate.


The company is also continuing with its submission in the UK, including the verification of the integrity of the Phase 3 clinical data. Potential regulatory approvals are expected in the first quarter of 2022.

Valneva further believes that VLA2001 has the potential to play a role in protecting against the Omicron variant, noting that it is being developed using the entire envelope of SARS-CoV-2, and not just the Spike protein like other vaccines.


Copyright (c) 2021 CercleFinance.com. All rights reserved.